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The use of microarray techniques for gene expression analysis provides a global view of 
the transcriptional activity in a biological sample. In this thesis two conditions 
accompanied by disturbance in the immune system are addressed following the changes 
in gene expression.  The first condition is hematopoietic stem cell transplantation (HSCT) 
and the second condition is chronic kidney disease (CKD).  A mouse model was used in 
studies related to HSCT, while human blood samples were used in the CKD study. 
In the first project, gene expression profiling in target and non-target organs after HSCT 
and during early development of acute graft versus host disease (GVHD) was 
investigated. The results show that both chemotherapy and allogeneicity induce 
expression of inflammatory genes in target tissues. Furthermore, gene expression in the 
kidney was similar to that observed in the liver, which is a target for developing GVHD.  
In conclusion, the kidney could be a possible target organ for GVHD.  
In the second project, the role of programmed cell death ligand-1 (PD-L1/CD274) in the 
development of graft versus host disease was studied. The expression of PD-L1/CD274 
was evaluated by PCR, western blot and immunohistochemistry at different time 
intervals after the development of acute GVHD. A significant up-regulation of PD-
L1/CD274 expression was observed in muscle and kidney at days 5 and 7 post allogeneic 
transplantation. The increase of CD274 expression was paralleled by high serum levels of 
IFN-γ and TNF-α at corresponding time points. In conclusion, our results confirm that 
PD-L1/CD274 expression is different after allogeneic and syngeneic transplantation, and 
that it is more expressed in non-target organs in the early stages of acute GVHD. This 
further indicates that the higher expression of PD-L1/CD274 in the muscle might have a 
protective role during acute GVHD. 
In the third project, changes in gene expression after two different conditioning 
regimens used in preparation for HSCT, either single dose or fractionated total body 
irradiation (TBI), were studied. In the lung, genes belonging to inflammatory and 
immune responses were intensely under-expressed upon conditioning with single-dose, 
but slightly increased by treatment with fractionated TBI. These genes remained 
unchanged in the liver and muscle upon conditioning with either of these regimens. Both 
the patterns and magnitudes of these effects were changed after 12 and 72 hours. Thus, 
pathological manifestations observed in the lung after conditioning with single-dose, but 
not fractionated, TBI can be associated with extensive down regulation of immune and 
inflammatory gene expression in this organ. 
In the fourth project, gene expression profile for monocytes from peripheral blood of 
chronic kidney disease (CKD) patients was performed. The results demonstrated 
differences from the gene expression profile of healthy persons. Pathways involved in 
the inflammatory response were highly expressed in CKD patients, and the Wnt/β-
catenin signaling pathway was the most significant pathway expressed in the patient 
group. Since this pathway has been attributed to a variety of inflammatory 
manifestations, the current findings may contribute to dysfunctional monocytes in CKD 
patients. Strategies for interfering with this pathway may improve host immunity and 
prevent cardiovascular complications in CKD patients. 
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1 INTRODUCTION 
1.1 THE IMMUNE SYSTEM  
The immune system has developed over time to protect the body from environmental 
pathogens. It keeps the individual from infectious agents such as bacteria, viruses, fungi 
or parasites. It also works to control certain intrinsic pathologic agents, such as tumor 
cells. Moreover, different chemical and physical agents induce immune response. 
The immune system consists of a highly organized network of organs, cells, and 
molecules. In healthy conditions, the immune system can distinguish foreign molecules 
from the body’s own and will attempt to destroy them. However, a strict control and 
regulation of the immune system is essential as both excessive and insufficient 
activation can be harmful, leading to autoimmunity and immune suppression 
respectively.   
Traditionally, the immune system is described as being composed of two components: 
the innate and the adaptive system. When a pathogen invades the body it is faced by the 
first line of defense, which consists of physical and chemical barriers such as skin, 
mucosal surfaces and low gastric PH. If a pathogen passes these barriers, the cellular 
part of the innate immune system will be activated.[1] The innate immunity is 
unspecific and lacks memory. 
The cellular part of innate immunity consists of different cells types that include 
neutrophils, natural killer cells (NK cells), monocytes, macrophages, dendritic cells 
(DCs), eosinophils, basophils, and mast cells. Together, these cells possess the ability to 
directly kill pathogens, produce compounds that enhance pathogen elimination and 
activate the adaptive branch of the immune system. 
The activation of the innate immune system depends on the recognition of highly 
conserved microbial structures via antigen receptors specific for certain patterns on the 
microbes. An example of such receptors is the toll like receptors (TLRs).[2]  Most 
pathogen invasions can be controlled by the innate immune cells, but sometimes extra 
response is needed. That is when the adaptive branch of the immune system becomes 
active. 
The innate immune response is rapid and responds within hours, while the adaptive 
immune response takes more time (days to weeks) but is more powerful. It has a very 
Chapter 1: Introduction 
 
2 Heevy Al-Chaqmaqchi 
 
high degree of specificity. Memory is the hallmark of adaptive immunity.[3]  The 
adaptive immune system consists of lymphocytes and their products. It can be divided 
into cellular immunity mediated mainly by T cells expressing T cell receptors (TCRs), 
exerting cytotoxicity and producing cytokines, and humoral immunity mediated by B 
cells expressing B cell receptors (BCRs).  The cells also have the ability to proliferate 
and clonally expand in response to an antigen in order to keep up with microbial 
replication. Lymphocytes are considered naïve before they meet certain cognate 
antigens, but when activated they can expand clonally and differentiate into many 
subtypes. After infection has been ended, most of the expanded lymphocyte 
populations die and balance is restored. Furthermore, some of the cells will be 
differentiated into memory cells that persist for many years and can respond very 
quickly upon re-infection by the same pathogen. 
1.1.1  T cells   
T-lymphocytes play an essential role in adaptive immunity. Precursors for T-
lymphocytes are present and start developing in the bone marrow, after which they 
undergo developmental changes in the thymus. They are therefore called T-
Lymphocytes (Thymus dependent). T cells have a receptor called T cell receptor (TCR) 
which is part of the T cell receptor complex. This complex is responsible for 
identification of the processed antigens presented by antigen presenting cells in the 
context of major histocompatibility complex (MHC) molecules. The TCR complex is 
formed by the TCR, CD3, and CD4 or CD8. Generally T cells are divided into CD4+ 
or CD8+ cells. 
CD4+ T cells recognize antigens presented to them in the context of MHC class II 
molecules. They have the ability to produce different types of cytokines, which helps 
other cells to differentiate and mature.[4]  After activation of CD4+ T cells, they can 
differentiate to different subsets such as Th1, Th2, Th17 and/or T regulatory cells, 
depending on the local environment, which are capable of inducing different kinds of 
immune response.[5-7] 
The CD4+ T helper 1 cells (Th1) predominantly produce interferon gamma (IFN-γ), 
interleukin 2 (IL-2) and tumor necrosis factor alpha (TNF-α). These cells mediate 
cellular immunity through enhancement of microbiocidal activity by monocytes and 
macrophages and by promoting the differentiation of cytotoxic lymphocytes, as well as 
regulating certain B cells responses. The CD4+ T helper 2 cells (Th2) produce 
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cytokines IL-4, IL-5, and IL-13, and by promoting mainly B cells to develop into 
antibody producing cytokines.[7]  
The CD8+ cells (also called cytotoxic T cells) recognize antigens in the context of 
MHC class I molecules or altered self-cells, e.g. virus infected cells.  When CD8+ cells 
activate, they produce large amounts of IFN-γ and TNF-α. They are very important in 
the killing of virus infected host cells, or intracellular microbes, as well as of tumor 
cells. They do not produce as much IL2 as CD4+ T cells, so they depend on CD4+ T 
cells to help them differentiate. The effects of IFN-γ produced by these T cells enhance 
the inflammatory response by activating macrophages and up regulating the expression 
of MHC classes I and II.[8] 
1.1.2 Monocytes 
Monocytes constitute 10% of peripheral blood leukocytes in humans and about 4% in 
mice. [9] Monocytes are members of the mononuclear phagocyte system.[10] They 
originate from CD34+ myeloid progenitor cells in the bone marrow and are released 
into the peripheral circulation, where they circulate for several days before entering 
tissues where they differentiate into macrophages or dendritic cells depending on the 
nature of environmental signals. For example, interferon-gamma switches monocyte 
differentiation from dendritic cells to macrophages.[11, 12]  The process of migration 
of monocytes to peripheral tissues involves several adherence-detachment events 
mediated by selectins and integrins on monocytes and endothelial cells.[13] 
Monocytes express CD14, which is a receptor for bacterial lipopolysaccharide (LPS). 
LPS binding to CD14 initiates transmembrane signaling and changes in cellular 
function. 
Monocytes play a central role in immunity, as they link the inflammation and the innate 
response to adaptive immune response by their wide communications.[14]  In addition 
they play an important role in development and homeostasis, via the removal of 
apoptotic cells and scavenging of toxic compounds. They are also implicated in many 
inflammatory diseases including atherosclerosis.[15, 16] 
1.1.3 Antigen presenting cells and activation of T cells 
Antigen-presenting cells (APCs) are specialized white blood cells that help to fight 
foreign substances that enter the body.  First, the APC engulfs the antigen. Enzymes 
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inside the APC break down the antigen into smaller particles. After that, the processed 
antigens are transported to the surface of the APC, and bound with an MHC class I or 
class II molecule. This complex forms epitopes that can be recognized and bound by  a 
TCR in the immune system.[17] 
The APCs are divided into two categories: professional and non-professional APCs. 
Professional APCs express MHC class II, while non-professional APCs express MHC 
class I.  
 There are three main types of professional antigen-presenting cells: macrophages, 
dendritic cells (DCs) and B-cells. These cells are able to engulf the antigen quickly 
during a process called phagocytosis.  
Non-professional APCs include fibroblasts (skin cells), thymic epithelial cells, thyroid 
epithelial cells, glial cells (brain cells), pancreatic beta cells and vascular endothelial 
cells. While almost every cell in the body is technically an APC because they can 
present antigens to T-cells, the term is usually used to describe professional APCs. 
When a T cell recognizes an antigen, the TCR binds to the peptide MHC complex in 
concert with either of the co-receptors CD8 or CD4, and this induces a signal in the T 
cell which is referred to as signal 1.  The naïve T cell needs at least two signals from an 
APC to become activated and a third signal to differentiate into different effector 
subsets.  
Signal 2 is the co-stimulatory signal that T cells receive from APCs to either promote 
or inhibit their survival and expansion. The most studied co-stimulatory molecules on 
the APCs are the B7.1 (CD80) and B7.2 (CD86) molecules that deliver signals via the 
CD28 molecule on the T cell.[18] 
The synergistic activation of the naïve T cells with TCR engagement and co-
stimulation via CD28 triggers the entry of the T cell into the G1 phase of the cell cycle, 
i.e. the initiation of cell division, and at the same time up regulation of the expression of 
IL-2 and the high affinity IL-2 receptor (CD25). IL-2 acts in an autocrine fashion to 
further clonally expand the T cell.[19] 
When the T cells have become activated they express other co-stimulatory or inhibitory 
molecules that may modify the T cell response. ICOS and CTLA-4 are two such CD28- 
related proteins where the first stimulates and the second inhibits the T cell. 
Programmed death one (PD-1) is another CD28 analogue which binds to programmed 
death ligand 1 and 2 (PD-L1 and PD-L2) which also belong to the B7 family.[20] It 
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inhibits T cell responses and mice lacking PD-1 develop autoimmunity. Another family 
of co-stimulatory molecules that up regulate after T-cell activation is the tumor necrosis 
factor superfamily (TNFSF).[8] Important receptor/ligand pairs included in this family 
are: CD137/CD137L, OX40/OX40L, CD30/CD30L, CD27/CD27L, and 
CD40/CD40L.   
There are several mechanisms that inhibit the activation of T cells by self-antigens, the 
most important being the lack of co-stimulation. APCs that introduce self-antigens are 
usually not activated and do not express co-stimulatory molecules. Moreover, most 
tissue cells cannot express these molecules at all, and consequently the T cells cannot 
respond to the self-antigens.  The T cells that recognize an antigen in the absence of co-
stimulation enter a state of anergy, which is defined as a state of unresponsiveness with 
no proliferation or IL-2 secretion by T- cells. The anergic T cell cannot respond to the 
antigen even if it is introduced later in association with induced co-stimulation.[21] It is 
believed that this mechanism helps maintain peripheral self-tolerance. However, there 
are many exceptions to this role and self-reactive or auto reactive T cell clones are 
present in many autoimmune disorders. When activated T cells clonally expand they 
also initiate programs of differentiation that turn them into effector cells with specific 
functions. CD8 T cells become cytotoxic and CD4+ T cells differentiate into helper 
cells.  
 Signal 3 instructs the activated T cells to switch on a particular set of genes that further 
help differentiate the T cells. This signal is an environmental stimulus that is not very 
well defined in many cases; however, in most instances the cytokines produced by 
nearby tissue decide what direction T cells will take. 
1.2 HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) 
The hematopoietic stem cell (HSC) is a pluripotent cell that has the capability to 
multiply to produce any type of blood cell in addition to its ability to renew itself and 
produce daughter HSCs. One of the features of HSCs is their capacity to return  to the 
marrow space after intravenous infusion.[22] HSCs either develop into lymphatic 
progenitor cells from which T and B lymphocytes are derived, or into myeloid 
progenitor cells from which granulocytes (neutrophils, eosinophils, and basophils), 
monocytes, erythrocytes, and megakaryocytes are derived (Figure 1).  
A single HSC can reconstitute the entire lympho-hematopoietic system in a syngeneic- 
transplanted animal after a dose of lethal total body irradiation.[23] 
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CD34 is a marker of HSC in humans, while in adult mouse bone marrow HSCs are 
detected in the CD34 low to negative fraction. CD34 low/- , c-Kit+, Sca-1 +, lineage 
markers negative (Lin-) are the usual markers for HSCs in mouse.[23, 24] 
 
 
Figure 1. Hematopoietic stem cell. From: http://www.sigmaaldrich.com/life-science/stem-cell 
biology/hematopoietic-stem.html 
HSCT can cure malignancy either by itself through immunological attack on cancer 
cells or by replacing the abnormal HSCs with normal ones. 
HSCT consists of several steps including: elimination of recipient stem cells, 
eradication of tumor cells, suppression of the recipient immune system and finally 
transplantation of stem cells from a suitable donor. Several factors must be considered 
when determining HSCT for a patient. These factors include: health condition, disease 
stage, type of transplantation and type and dose of conditioning regimen.[25-27] 
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1.2.1 History of hematopoietic stem cell transplantation (HSCT) 
In the last two decades, HSCT has become the curative treatment for many non-
malignant diseases as for severe combined immune deficiency disease (SCID), 
thalassemia and sickle cell anemia, as well as malignant diseases and different 
metabolic disorders.[22, 28-32] The HSCT started with the observation that  animals 
could escape death from a lethal dose of irradiation by protecting their spleen and/or  
their femur with a lead sheet.[33] Soon after, Lorenz and his colleagues found that 
protection could be also issued with an intravenous infusion of bone marrow.[34]  The 
exact cause of the cure was unknown until later, when stem cells were identified. Early 
studies in humans were carried out by Donnall Thomas and colleagues in 1955.[35] 
Although the early studies were disappointing, they opened the way for wider studies. 
All these studies and experiments were carried out before we had knowledge of 
histocompatibility. They were based on inbred mice which do not require 
histocompatibility, which led to very high mortality if not a complete lack of success. 
After that in 1968 Storb, Epstein et al identified the canine major histocompatibility 
complex dog leukocyte antigen (DLA) and they showed that this determines the 
outcome of transplantation.[36] Furthermore, Epstein et al started to use 
cyclophosphamide in place of total body irradiation (TBI) for conditioning prior to 
transplantation.[37, 38] 
1.2.2 Sources of HSCs 
Previously, bone marrow (BM) was the only source of HSCs for transplants, as there 
are ten times more of them in the BM than in the peripheral blood (PB). However, 
HSCs are still rare cells in the bone marrow. They represent 0.01% of all the cells in 
BM.[39] BM is not a solid organ, but rather diffuse and not easily accessible. During 
the last 20 years the majority of stem cell transplantation have been carried out using 
stem cells collected from peripheral blood after stimulation with granulocyte colony –
stimulation factor (G-CSF).[40]  Earlier engraftment of neutrophils and platelets has 
been reported in HSCT using PB stem cells compared to other stem cell sources.[41, 
42] However, the use of PB stem cells showed an increased risk of extensive graft 
versus host disease (GVHD).[40, 43, 44] Currently cord blood stem cells are used 
widely and reports has shown that the rate of engraftment is high and risk of severe 
GVHD is low.[45, 46] However, the number of HSCs that are present in a single unit of 
cord blood is not enough for transplantation to an adult patient, and more than one 
donor is needed.[47] Patient age, underlying disease and timing of transplant are 
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important factors in determining type of transplant. Furthermore, the type and 
accessibility of donor may influence the transplant protocol used. 
1.2.3 Major histocompatibility complex and types of HSCT 
Prior to performing HSC, it is important to have an essential procedure done - MHC 
screening. The histocompatibility matching is one of the factors that play a major role 
in transplantation results. The MHC is a genetic locus with principal encoded proteins 
which present peptides to T cells. It plays important role in transplantation, immunity, 
inflammation, infections and different diseases.[48, 49] 
Concerning the genetic difference between donor and recipients, HSCT could be 
divided into three types: 
 Autologous, HSCs from the person himself, which have been preserved. 
 Syngeneic, HSCs from an identical twin, i.e. they have similar major 
histocompatibility complex (MHC). 
 Allogeneic, HSCs from a different MHC; this could be a sibling or a non-
related donor. 
In humans, MHC molecules are called human leukocyte antigens (HLA). The gene 
groups are present in chromosome number six. The complex region is divided 
conventionally into three classes; class I, II and III, each containing a cluster of genes 
with related functions.  
Class IA and B proteins are found on the surface of nucleated cells in the body and 
present endogenous antigens to the cytotoxic CD8+ T cells,[50] while HLA-C is 
associated with natural killer (NK) antigen recognition. In the past, HLA-A and HLA-B 
were the only class I antigens routinely typed for transplantation, but it has recently 
been shown that differences at the HLA-C locus may be associated with higher rates of 
graft rejection and GVHD following unrelated donor stem cell transplantation.[51]  
MHC class II are found on the antigen presenting cells such as B cells, monocytes and 
dendritic cells.[50] They present the exogenous antigens which are taken up by 
endocytosis or phagocytosis to helper CD4+ T cells. Class III genes encode the 
components of the complement system that target foreign cells and break their 
membranes.  
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The importance of matching patient and donor for HLA class I (A and B) and class II 
(DR) has long been established.[52-54]  At present, evaluation of HLA typing using 
molecular techniques is mandatory.[55]  
The patient’s HLA type (HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQB1 and 
HLA-DPB1) is generally defined using DNA-based HLA typing techniques. These are 
based on PCR using sequence specific primers or sequence specific oligonucleotide 
probes.  
HSCT with an HLA identical sibling donor is associated with the best transplant 
outcome.[56] However, the chances of finding a fully matched unrelated donor is about 
30% to 70%.[57]  Alternative related donors may be used with an increasing degree of 
HLA mismatching, including a haploidentical donor, which applies to 15% to 50% of 
patients.[58-60] The importance of MHC similarity and relationship between donor and 
recipient is clear from the lower risk of mortality and infection, the overall survival, and 
the decreased risk of GVHD.[61-63] Moreover, immune reconstitution occurs at an 
earlier time in patients with matched and related donors compared to in patients with 
mismatched donors.[64] However, a certain grade of MHC disparity is required when 
HSCT is used in malignancies where strong graft versus leukemic (GVL) effect is 
necessary.[65] 
1.2.4 Conditioning and HSCT 
Prior to carrying out HSCT it is essential that the patient is prepared by receiving 
conditioning agents. Generally, conditioning can be divided into two types according to 
the agent used, chemotherapy or total body irradiation (TBI). Furthermore, a 
combination of both is widely used. Sometimes other agents, for example anti-
thymocyte, are added to the conditioning regimen.[66, 67] It has been shown that 
addition of anti-thymocyte to the conditioning regimen reduces graft failure. 
The purpose of the conditioning is to provide a space for the new donor stem cells, to 
eliminate tumor and dysfunctional stem cells, and to suppress the immunity of the 
recipient in order to prevent rejection of the transplanted cells. All conditioning 
regimens, regardless of their intensity, induce some tissue damage which leads to 
inflammatory cytokine release.[68]  Moreover, the residual host immune cells which 
survive after conditioning have an important effect on bone marrow transplantation 
(BMT) results and complications.[69, 70] The choice of conditioning protocol depends 
on different factors such as the underlying disease, the patient’s age and the availability 
of facilities.[71, 72]  
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According to the intensity of the protocol, conditioning can be divided into two groups:  
 Myeloablative regimens which are performed by using the maximum tolerable 
dose of the regimen used. This regimen results in severe pancytopenia within a 
few weeks from its start. The resulting pancytopenia is usually irreversible, and 
requires an infusion of hematopoietic stem cells for survival. 
 Non-myeloablative regimens or reduced intensity regimens (RIC) cause 
reversible cytopenia. They have been used in clinics for more than a 
decade.[73] 
RIC has been used for older patients.[74-76] Similarly RIC is starting to be used more 
in children.[77-79]  Different studies in patients with acute myeloid leukemia have 
shown that transplant related mortality was decreased but relapse was increased in 
patients treated with RIC.[80] Reports have shown that the intensity of conditioning is 
important in the development of complications including GVHD.[81] 
1.2.4.1 Total body irradiation (TBI) 
The first conditioning regimen introduced to clinical HSCT was TBI.[35]  TBI is an 
effective myeloablative treatment able to eradicate tumor cells. It has been used at low 
doses of less than one Gray (Gy) for various malignant disorders since 1900.[82]  Even 
though the exact mechanism of action of radiation is not fully understood, it is 
suggested that the free radicals that are induced during the radiation process cause 
damages in the DNA chain, which finally leads to cell death. There is no exact optimal 
dose for TBI.  Early myeloablative TBI regimens used single, large dose fractions of 8-
10 Gy.[83-85]  These kinds of regimens were accompanied by high risk of death from 
interstitial pneumonitis.[86, 87] It has been shown that fractionation and reduction of 
the dose reduce the risk of development of this complication.[87-89]  Results from 
numerous studies showed that in both humans and rodents, dose rates of less than 10 to 
12 cGy/min are associated with reduced rates of pneumonitis, nausea and vomiting.[88, 
90, 91] 
During radiation of the whole body, toxicity to every organ should be considered. 
However, it is difficult to assess the toxicity which is associated directly with TBI 
because other treatments such as antibiotics, antifungals, immunosuppressants, pain 
killers and chemotherapeutic agents are administered simultaneously during the BMT 
process.  
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Other main complications of TBI include secondary malignancy [92], cataracts [93, 
94], growth retardation (especially in children) [95],  veno-occlusive disease, interstitial 
pneumonitis, endocrine and central nervous system complications.[82]  
In order to reduce the volume of total tissue exposed to radiation, blocks are used to 
protect different organs, e.g. lungs and eyes, without affecting the efficacy of treatment. 
Furthermore, cyclophosphamide (Cy) was added to the conditioning protocols in order 
to increase the immunosuppressive effect, decrease radiation toxicity and prevent graft 
rejection.[96] 
1.2.4.2 Chemotherapy 
Different chemotherapeutic agents have been used for conditioning procedure during 
preparation for HSCT. Busulfan (Bu), cyclophosphamide (Cy) and Fludarabine are 
widely used in addition to other agents such as chlorambucil, cytosine arabinoside, 
melphalan, thiotepa, carmustine, and etoposide.  
Bu in combination with high-dose Cy is one of the most common conditioning 
regimens. It is a standard conditioning protocol for HSCT.[74]   
Cy is an alkylating agent that belongs to the nitrogen mustard group. It is a pro-drug 
that is converted in the liver into active forms that have chemotherapeutic effects. It has 
been used in clinical practice since 1958 and is currently one of the most commonly 
used agents for treating various types of cancers and autoimmune disorders.[97, 98]  
Cyclophosphamide is converted to active metabolites by mixed-function oxidase 
enzymes in the liver [99] The main active metabolite is 4-hydroxycyclophosphamide, 
which exists in equilibrium with its tautomer, aldophosphamide. Most of the 
aldophosphamide is oxidized by the enzyme aldehyde dehydrogenase (ALDH) to make 
carboxyphosphamide. A small proportion of aldophosphamide is converted into 
phosphoramide mustard and acrolein. Acrolein is toxic to the bladder epithelium and 
can lead to hemorrhagic cystitis. This can be prevented through the use of aggressive 
hydration and/or mesna. The main effect of cyclophosphamide is due to its metabolite 
phosphoramide mustard. This metabolite is only formed in cells that have low levels of 
ALDH.[100, 101] However, it has been shown that it may also reduce the number of 
bone marrow stem cells and progenitor cells  through damage to the stromal supportive 
cells.[102]  
Bu is another alkylating agent that has reduced the use of TBI since its introduction to 
the BMT field. It has been used as a treatment for chronic myeloid leukemia.[103] 
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However, its use as a myelosuppressive agent in conditioning prior to HSCT was 
introduced in the 1990’s.[104-107]   Bu is given orally or intravenously. It displays a 
more marked effect on myeloid cells than on lymphoid cells. It is cytotoxic to 
hematopoietic stem cells. Prolonged aplasia may be seen after Bu administration.[102, 
108] 
Busulfan metabolism and detoxification as well as cyclophosphamide activation is 
mainly done in the liver.[97, 101, 109] Busulfan is metabolized primarily through the 
liver by conjugation to reduced glutathione (GSH). This process depletes hepatocyte 
glutathione stores. It has been shown that a high load of toxic metabolites and a 
shortage of protective components (e.g. GSH) during Bu-Cy conditioning induce 
hepatic toxicity and liver injury.[27, 110] A couple of studies concerned with altering 
the sequence of Bu and Cy administration have shown that this will give the same level 
of engraftment and also reduce the toxicity of the conditioning regimen.[111, 112]  
1.2.5 Complications of HSCT 
HSCT has become the standard treatment for many types of malignant and non-
malignant disorders. Unfortunately, HSCT is often associated with severe 
complications. These complications can be acute (i.e. early) or late. Moreover, these 
complications may be due to the conditioning process or to the transplantation itself. 
Infection due to different etiology is a very dangerous early complication. Deficiency in 
cellular and humoral aspects of the immune system occurs to some degree in every 
HSCT recipient. Usually recipients of allogeneic HSCT are highly susceptible to 
infections because of immunodeficiency, neutropenia, and immune suppressive therapy 
used to prevent or to treat GVHD. Different bacterial, viral and fungal infections can 
occur. The viruses that are regarded as most important in the HSCT setting include the 
herpes virus family, specifically cytomegalovirus (CMV), Epstein-Barr virus (EBV), 
and human herpes virus 6, as well as human adenoviruses and the polyoma virus 
BK.[113-119] 
Veno-occlusive disease (VOD) also known as sinusoidal obstructive syndrome (SOS) 
is another common complication. The symptoms of VOD start 1 to 4 weeks after 
conditioning. It occurs in 20 to 50% of patients receiving high dose TBI and those 
receiving high doses of cyclophosphamide and busulfan without TBI.[27, 120, 121]  
The risk factors include pre-transplantation elevation of serum aminotransferase, 
intensive conditioning therapy, graft from mismatched or unrelated donor and use of 
antimicrobial therapy with Acyclovir, amphotericin B, or Vancomycin.[122] The 
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pathogenesis behind VOD development is not well known. It is thought that the 
obstruction of the venules by endothelial cell injury and thrombosis is the main 
pathology behind this condition. 
Graft failure is another early or late complication after allogeneic HSCT. It is evidenced 
by lack of early or late hematopoietic recovery in association with recurrence of the 
disease or reappearance of the host cells after initial donor cell engraftment. The 
incidence of marrow engraftment failure is rare, i.e. less than 2% in patients with 
hematologic malignancies receiving complete HLA identical marrow. The 
complication is more commonly seen in patients with aplastic anemia receiving 
allogeneic BMT.[123] 
Several late complications can occur after HSCT. These include endocrine 
complications.[124] Hypo- or hyperthyroidism could occur.[125, 126] Growth 
hormone deficiency has been reported, mainly in children conditioned with high dose 
TBI.[127] Impaired sexual maturity and infertility are common complications in those 
treated with TBI,[128] and there is also a high incidence of cataracts.[129, 130] 
Neurological toxic effects include leukoencephalopathy, cerebral ataxia, and seizures as 
possible late complications. This is especially the case in children receiving irradiation 
or intrathecal chemotherapy.[131-133]  
Aseptic necrosis of the hips has been reported after HSCT.[134, 135]  There is also an 
increased incidence of secondary malignancies.[136] Other complications include 
respiratory failure from multiple etiologies, GVHD, multi organ failure, hemorrhagic 
cystitis and mucositis.[137-141]  
1.2.6 Graft versus host disease (GVHD) 
GVHD is a one of the major complication after allogeneic HSCT.[142]  The  
development of GVHD can be divided into acute, which occurs within the first 100 
days after transplantation, and chronic, which starts after 100 days.[143] However, the 
mechanism and the pathological features of these two entities are different. Moreover, 
acute GVHD can be developed beyond 100 days in patients transplanted using non 
myeloablative conditioning.[144, 145] The incidence of acute or chronic GVHD 
fluctuates between different centers; however, acute GVHD develops in 40% to 70% of 
all allogeneic-transplanted patients while chronic GVHD may occur in 28% to 100% of 
patients.[146]  
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During GVHD, immune cells from the donor identify the host environment as a foreign 
environment and start to attack different tissues in the recipient leading to development 
of fatal symptoms.[147, 148] The donor T cells are among the cells responsible for 
acute GVHD; CD4+ and CD8+ αβ T cells are reported to be the main inducers of 
GVHD by different mechanisms.[149-152]  
 Acute GVHD is characterized by dermatitis, hepatitis and enteritis. A maculopapular 
rash involving the trunk, face, extremities, palms, soles of the feet and ears usually 
characterizes the onset of acute GVHD. The liver function tests including alkaline 
phosphatase, and aminotransferase levels increase in addition to increased levels of 
bilirubin. These signs are usually accompanied by gastrointestinal symptoms such as 
nausea, vomiting, abdominal pain and massive watery or bloody diarrhea. Acute 
GVHD is graded as I-IV based on severity of involvement of the target organs for 
GVHD such as skin, liver, and gastrointestinal tract.  
It is presumed that conditioning induces tissue damage and subsequent 
lipopolysaccharide (LPS) extravasation from the damage to the gastrointestinal tract 
(GIT), promotes inflammation and cytokine storm and leads to activation of donor T 
cells by host/donor APCs.[147, 148, 153, 154]  
However, three basic components for developing GVHD have been suggested by 
Billingham.[155] First, the graft should contain immune competent cells, mostly donor 
T lymphocytes. [156, 157] Second, the recipient must have low immunity and be 
unable to reject transplanted cells and third, the recipient tissues must present antigens 
that are not expressed by the donor’s cells.[158]  
Acute GVHD occurs as a consequence of donor T cell recognizing the recipient HLA 
antigens as foreign, starting to attack tissues of the host and developing signs and 
symptoms of acute GVHD.[143] The tissue damage occurring in acute GVHD may be 
mediated by infiltration of the target organ by natural killer lymphocytes. Interleukin 1 
(IL-1), tumor necrosis factor (TNFα), and IL-2 are thought to be critical to the 
development of acute GVHD.[159]  
Different studies reported that GVHD develops in three sequential stages. i) 
Inflammation and cytokine storm as result of pre-transplant conditioning. ii) Activation 
of donor T cells through recipient/donor APC and iii) Damage of certain tissues by the 
activated donor T cells.[153, 160-167]  Intestine, skin, and liver are the organs most 
frequently affected by allo-reactive donor T cells in the GVHD process.[168]   
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Investigations have shown that the occurrence and severity of GVHD depend on 
several factors including: intensity of pre-transplant conditioning, presence and number 
of donor T cells, antigenic difference between donor and recipient with a high risk in 
HLA mismatch and unrelated HLA identical donor [81, 163, 169, 170], female donor 
to male recipient (previous donor pregnancies), increase in donor or recipient age, 
unsuccessful GVHD prophylaxis and previous recipient infections with herpes viruses. 
However, GVHD may occur in any type of allogeneic setting regardless of 
conditioning protocol.[144, 171]  
1.3  CHRONIC KIDNEY DISEASE (CKD) AND IMMUNITY 
CKD is the slow loss of kidney function over time. It is a general term used to describe 
a wide scope of disorders affecting the function and histology of the kidney. The major 
causes are glomerulonephritis, diabetes mellitus, nephrosclerosis, interstitial nephritis, 
and polycystic kidney disease. It is usually associated with diabetes, hypertension, 
obesity, and old age in developed countries. However, the exact pathology is 
unknown.[172]  
For defining CKD, we depend on the presence of albuminuria or decreased renal 
function, i.e. a glomerular filtration rate (GFR) of less than 60 ml/min per 1.73m
2
 for 
three months or, more independently, on the appearance of clinical signs. 
Kidney function can be measured either directly by measuring the GFR [173, 174], or 
indirectly by determining the concentration of creatinine in the serum. Measuring 
creatinine concentration in serum is fast and simple, and it is the most commonly used 
screening test for renal function; however, as much as 50% of the nephrons may be lost 
before the creatinine levels increase. Furthermore; the levels of creatinine are 
influenced by extra-renal elimination, muscular mass, body mass, age and diet.[175]  
The National Kidney Foundation in the United States classified CKD into five stages 
based on the level of GFR. Stage I denotes normal or elevated GFR (more than 90 
ml/min per 1.73 m
2
), stage II is 60 to 89 ml/min per 1.73 m
2
, stage III is 30 to 59 
ml/min per 1.73 m
2
, stage IV is 15 to 29 ml/min per 1.73 m
2
, and stage V represents a 
GFR of less than 15 ml/min per 1.73 m
2
 or treatment with dialysis and this is called end 
stage renal failure.  
When end stage renal disease is developed, patients are in increased risk of 
susceptibility to infection complications.[176-178] Impairment of defense mechanisms 
is responsible for the increased susceptibility; however, dysfunctional 
polymorphonuclear cells are a contributing factor.[179] This dysfunctionality is 
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exhibited as reduced chemotaxis, decreased phagocytic ability, reduced intracellular 
killing and increased apoptosis rate.[180, 181]  In addition, these patients display 
extended survival of skin allograft, reduced immunization against hepatitis B, 
diphtheria, influenza, and tetanus vaccine, which indicates immune defects in antigen 
presenting cells.[182-186] Malnutrition, loss of vitamins, iron overload, and uremic 
toxins also contribute to leukocyte dysfunction.[179, 187] CKD is associated with an 
acquired immune deficiency concerning both cellular and humoral immunity. 
 These patients have been identified as being in a state of low grade inflammation, 
which renders them less responsive.[188] The state of immune dysfunction that occurs 
in uremia can be characterized by the presence of both immunoactivation and 
immunodepression.[189] Despite the increased secretion of proinflammatory cytokines, 
both monocytes and monocyte-derived cells might have a reduced antigen presentation 
capacity in patients on chronic hemodialysis.[189] The impaired expression of co-
stimulatory molecules also contributes to this phenomenon.[190]  
Studies in patients on dialysis showed that reduced renal clearance of cytokines might 
contribute to elevated cytokine levels in peripheral blood.[191] Importantly, an increase 
in plasma levels of proinflammatory cytokines is associated with mortality in patients 
on dialysis.[192] 
In addition, different studies have reported an increased risk of accelerated 
atherosclerosis in CKD.[193-195] Atherosclerosis is an inflammatory disease which 
attributes a pivotal pathophysiological role to monocytes and macrophages. Monocytes 
are considered instrumental in the development of atherosclerosis from the earliest 
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2 AIMS 
2.1 GENERAL AIMS 
The overall aim of this thesis is to investigate changes in gene expression during 
conditions accompanied by disturbance in immune system, with a special concern to 
hematopoietic stem cell transplantation and chronic kidney disease. The goal is to gain 
insight into the mechanisms responsible for these conditions and to identify new 
pathways that can contribute to the development of new treatment strategies and give 
further understanding of the pathophysiology of the disease. 
2.2 SPECIFIC AIMS 
 To study the gene expression profile early after HSCT in target organs and non-
target organs of acute GVHD, and to find out whether specific pathways 
characterize target and non-target organs.   
 To define the role of expression of PD-L1/CD274 in different organs early after 
HSCT and to understand the importance of this expression in protecting non-
target organs from GVHD. 
 To evaluate the gene expression profile and hence to assess immunological 
changes that accompany different strategies used for delivering TBI, either 
single dose or fractionated, during conditioning before hematopoietic stem cell 
transplantation.  
 To investigate the gene expression profile of monocytes from CKD patients in 
comparison to healthy persons and to find activated pathways in this patient 
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3 MATERIALS AND METHODS 
3.1 ANIMALS  
In papers I, II, and III, female BALB/c (H-2Kd) and male C57BL/6 (H-2Kb) mice 
obtained from Scanbur (Sollentuna, Sweden) were used. The mice were 10 to 14 weeks 
old at the time of the experiments. Animals were kept in individually ventilated cages 
and maintained under specific pathogen free conditions in an animal facility with 
controlled humidity (55% ± 5%), 12 hours light/dark cycle, controlled temperature 
(21ºC ± 2ºC) and HEPA filtered air. The animals were fed autoclaved mouse chow and 
tap water ad libitum, and were allowed to acclimatize to their surroundings for one 
week before the start of the experiments. All animal experiments were approved by the 
Stockholm southern ethical committee and in accordance with the Animal Protection 
Law, the Animal Protection Regulation and the regulation of the Swedish National 
Board for Laboratory Animals.  
For bone marrow transplantation in the syngeneic setting, female BALB/c (H-2Kd) 
mice were used as recipients and female BALB/c mice were used as donors, while in 
the allogeneic setting female BALB/c mice were used as recipients and male C57Bl/6 
(H-2Kb) mice were used as donors. Untreated mice were used as controls whenever 
appropriate. 
3.2 CONDITIONING  
The chemotherapy conditioning for paper I and II consisted of Bu 20 mg/kg/day for 
four consecutive days (day -7 to day -4) followed by Cy 100 mg/kg/day for two days 
(day -3 and day -2). This six day regimen was followed by one day of rest (day -1) and 
then bone marrow transplantation the day after (day 0). Both Bu and Cy were 
purchased from Sigma-Aldrich (Sigma-Aldrich Stockholm, Sweden). Both drugs were 
given through intra-peritoneal injection. For irradiation-based conditioning in paper III, 
mice received total body irradiation of 850 cGy either as a single dose or two 
fractionated doses employing a cesium source (Gammacell® 40 Exactor, Best 
Theratronics, Ottawa, Ontario, Canada).   
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3.3 BONE MARROW TRANSPLANTATION  
For preparing bone marrow the donor mice (either allogeneic or syngeneic setting) 
were sacrificed by cervical dislocation. Bone marrow cells (BMC) were flushed from 
both femurs and tibias. Single-cell suspension was prepared by passing cells gently 
through a 14G needle in RPMI-1640 containing 2% fetal bovine serum (FBS). The 
cells were then centrifuged and washed with RPMI. Donor spleens were disrupted in 
RPMI-containing 2% FBS to form a single cell suspension. Splenocytes were passed 
through a 70 μm strainer, centrifuged and washed two times with RPMI. Cell number 
and viability was measured using Trypan blue exclusion dye. Recipient mice received 2 
x 10
7
 BMC in combination with 3 x 10
7
 splenocytes intravenously through the lateral 
tail vein in a volume of 200 μl in PBS (Phosphate buffer saline). 
3.4 TISSUE PREPARATION  
In all experiments involving mice, the entire mouse body was perfused through the 
heart with 20 to 30 ml ice cold PBS containing 2% FBS 10mM EDTA until the organs 
became pale in order to exclude any confusing effects of circulatory cells in tissues. 
Parts of the tissue were then snap frozen in liquid nitrogen and transferred to -150 ºC 
until used. 
3.5 ASSESMENT OF GVHD  
Recipient mice were checked daily from the start day of conditioning until the day of 
taking samples. They were evaluated for five signs: weight loss, posture, activity, fur 
texture and skin integrity. These signs represent signs of acute GVHD in mice. The 
severity of each given symptom was scored from 0 to 2. The sum of the scores for all 
symptoms in each mouse (maximally 10) was used as an index of the severity and 
progression of GVHD. 
3.6  RNA PURIFICATION  
Total RNA from frozen sections was extracted with the Qiagen RNeasy kit (WVR, 
Stockholm, Sweden) according to the manufacturer’s instructions. The integrity of 
extracted RNA was confirmed using the NanoDrop ND-1000 (NanoDrop 
Technologies, Wilmington, DE) with extracts exhibiting absorbance in a ratio of 1.90 
to 2.0 at 260/280 nm being regarded as of acceptable purity, and agarose gel was run to 
confirm purity of RNA. 
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3.7 CDNA SYNTHESIS FOR MICROARRAY ANALYSIS  
3.7.1 Affymetrix  
Double-stranded complementary DNA (cDNA) was synthesized with 50 ng of total 
RNA using the SuperScript Choice system (Invitrogen Inc). T7-(dT24) oligomer was 
used for priming the first-strand cDNA synthesis. The resultant cDNA was purified 
using the Sample clean up kit (Affymetrix Inc). The cDNA pellet was collected and 
dissolved in an appropriate volume. Using cDNA as the template, cRNA was 
synthesized using an In-vitro transcription (IVT) kit (Affymetrix Inc). IVT reactions 
were carried out at 37°C for 16 hours and the labeled cRNA was purified using the 
Sample clean up kit (Affymetrix Inc). The cRNA was fragmented in a fragmentation 
buffer (40 mmol/l Tris-acetate, pH 8.1, 100 mmol/l KOAc, 30 mmol/l MgOAc) for 35 
min at 94°C. Fragmented cRNA (15 µg/probe array) was hybridized with Mouse 
Genome 430 2.0 GeneChip arrays (Paper I) or Human U133A GeneChip arrays (Paper 
IV) at 45°C for 18 hours in a hybridization oven with constant rotation (60 rpm). The 
chips were washed and stained using the Affymetrix fluidics station. Staining was 
performed using Streptavidin phycoerythrin conjugate (SAPE; Molecular Probes, 
Eugene, OR, USA), followed by the addition of a biotinylated anti-Streptavidin 
antibody (Vector Laboratories, Burlingame, CA, USA), and finally with Streptavidin 
phycoerythrin conjugate. Probe arrays were scanned using fluorometric scanners 
(Affymetrix Scanner). The scanned images were visualized and analyzed using 
established quality control criteria. 
3.7.2  NimbleGen  
Double stranded cDNA was prepared from 10 µg total RNA as a starting material, 
using the Invitrogen Superscript Double-Stranded cDNA Synthesis Kit. Clean up of the 
cDNA was done. Then 1µg of cDNA was used in labeling with Cy3 by NimbleGen 
One-Color DNA Labeling Kit.  4µg of labeled cDNA was used for hybridization to a 
NimbleGen array (12 plexus gene array was used, 12x135K (12 x 132,510 probes equal 
to 44170 genes)) using a NimbleGen Hybridization System. Subsequent steps include 
washing, drying, and scanning the array with the MS 200 Microarray Scanner and the 
MS 200 DATA Collection Software. 
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3.8 REAL-TIME PCR (RT-PCR)  
Total RNA was used to synthesize single strand cDNA by using Superscript II reverse 
transcriptase system and oligo dT12-18 according to manufacturer’s instructions 
(Invitrogen Inc., CA, USA). Using cDNA as a template, TaqMan gene expression 
assays were performed by means of the FAM dye labeling system according to the 
manufacturer’s instructions (Applied Biosystems, Stockholm, Sweden). TaqMan assay 
for selected genes and the house keeping gene β-actin (Actb) were used for detection of 
genes (Applied Biosystems, Stockholm, Sweden). 
RT-PCR reactions were performed using a 384 well plate in the ABI 7900 Thermal 
cycler (Applied Biosystems, Stockholm, Sweden). The results were normalized against 
the house keeping gene Actb  by subtracting the Ct value of house-keeping gene from 
Ct of the specific gene (Ct gene- Ct Actb) giving a delta Ct (∆Ct) value. Relative gene 
expression was calculated using the equation 2 -∆Ct. The value of ΔΔCt for an 
individual gene, when comparing day of interest to control, was calculated by 
subtracting ΔCt of control from ΔCt of specific time point (ΔCt specific day -ΔCt of 
control) and the fold change was calculated using the equation 2 -∆∆Ct.  
3.9 IMMUNOHISTOPATHOLOGY  
Tissue samples were fixed in neutral buffered formalin for 24 hours, transferred to 70% 
ethanol, dehydrated and embedded in paraffin according to standard procedures. 
Sections of 4μm were prepared, mounted on glass slides and routinely stained with 
H&E or prepared for immunohistochemistry. 
After rehydration in a graded alcohol series and antigen retrieval, sections were treated 
with 0.3% H2O2 for immunohistochemistry staining for PD-L1/CD274 (Paper II) to 
block endogenous peroxidase activity. After blocking with 10% goat serum, samples 
were incubated overnight with goat anti-mouse PD-L1 (R and D Systems) and diluted 
in 2% bovine serum albumin/phosphate-buffered saline as the primary antibody. After 
washing, sections were incubated with horseradish peroxidase (HRP)-conjugated rabbit 
anti-goat IgG (ZYMED Lab, Invitrogen), at 1:500 dilution. Sections were developed 
using the HRP-DAB system (R and D Systems), counterstained with Mayer’s 
hematoxylin (Sigma), dehydrated through a graded alcohol series, and cover slipped. 
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3.10 PATIENTS  
Patients with renal failure were recruited from the Department of Nephrology at 
Danderyd Hospital. All participants gave their written informed consent and the study 
was approved by the Ethics committee of the Karolinska Hospital. All patients and 
healthy subjects suffering from infectious diseases, diabetes mellitus or active 
inflammatory diseases as well as those receiving antibiotics, corticosteroids or non-
steroidal anti-inflammatory agents were excluded from the study. 
The study population consisted of fourteen patients with severe renal failure (GFR less 
than 20 ml/min per 1.73 m
2
 according to the Cockcroft and Gault equation) and ten 
healthy subjects. The healthy subjects were age and sex matched with the patients. The 
renal diagnoses were the following; nephrosclerosis, polycystic kidney disease and 
renal failure of unknown origin. 
3.11 MONOCYTES (COLLECTION & PURIFICATION)  
50-60 ml of peripheral blood was collected in 9 ml tubes containing 135 USP U sodium 
heparin (Venosafe, Terumo Europe, Leuven, Belgium). Monocytes were isolated from 
the peripheral blood by density centrifugation. Briefly, blood was diluted 1:1 with 
RPMI 1640. The diluted blood was then layered on 25ml Ficoll-Paque (Pharmacia 
Biotech, Uppsala, Sweden) and centrifuged at 400 
x
g in room temperature for 30 
minutes. The monocyte rich white color band was collected. A positive selection of 
monocytes was performed by incubating the monocytes with anti-CD14 coupled to 
MACS beads (Miltenyi Biotec, Auburn, California, USA). The cells were then loaded 
onto a MidiMACS column and the CD14 positive monocytes were collected.  
3.12 PURITY OF MONOCYTES BY FLOW CYTOMETRY  
The purity of monocyte fraction was analyzed by flow cytometry (Beckman Coulter 
Inc., Hialeah, Florida, USA). This instrument gives the actual number of cells and the 
mean fluorescence intensity (MFI). Monocyte cell populations were distinguished by 
their different light scattering properties (Forward Scatter (FS)/Side Scatter (SS)). The 
forward scatter signal (y-axis) reflects the cell size while the side scatter signal (x-axis) 
reflects cell granularity. The percentage and absolute number of positively 
immunostained monocytes was determined by measuring MFI of the positive cell 
population after staining with CD14–ECD (Beckman Coulter, Marseille, France) and 
using isotype mouse IgG2 (Beckman Coulter, Marseille, France). Only fractions above 
95% purity were used for further experiments.  
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3.13 MEASURING TNF-  AND IFN- BY SANDWICH ELISA   
At different time points before and after transplantation, the mice were bled by retro-
orbital puncture under light isoflurane anesthesia and thereafter sacrificed by cervical 
dislocation. The blood samples were centrifuged to obtain serum, which was stored at 
−80°C until analysis. The levels of TNF- and IFN- in the sera were quantified 
employing commercially available ELISA kits (eBiosciense, San Diego, CA, USA), in 
accordance with the manufacturer’s instructions. 
3.14 WESTERN BLOT  
Lysate for western blot was prepared in the following manner: for paper IV, whole cell 
lysate was used, and for paper II, 10-20 mg frozen samples of muscle, liver and kidney 
from different time points were used. 
Isolated purified monocytes were washed with cold PBS and lysed in modified 
radioimmunoprecipitation assay buffer (modified RIPA). Two cycles of freezing and 
thawing on dry ice with ethanol were completed, and then the sample was left in ice for 
30 min. Debris was removed by centrifugation at 10000 rpm for 10 min at 4ºC and the 
supernatant was collected. 
Tissues samples were finely minced with a lancet and subjected to interrupted cycles of 
sonication. Using the probe sonication, the instrument was adjusted to a 0.5 cycle and 
the cycle amplitude to 50 kHz. Samples were subjected to 10 short bursts of 10 second 
duration followed by intervals of 30 seconds for cooling, and the procedure was 
repeated several times until complete lysis was achieved. The lysates were centrifuged 
at 16 000 rpm for 15 minutes at 4ºC and the supernatant was collected. Measuring of 
protein concentration was done by special available commercial kits.    
Protein samples were then stored in sample buffer containing 0.0625M Tris-HCl pH 
6.8, 2% SDS, 10% glycerol and 0.025% bromophenol blue.  
The lysates in sample buffer were boiled at 95°C for 5 minutes and separated by special 
gels. Gels were blotted on a polyvinylidene fluoride membrane (Immobilon-P, 
Millipore, Bedford, MA) or nitrocellulose membranes. The membranes were blocked 
in 5% milk followed by incubation with primary antibodies overnight.  After washing, 
the membranes were incubated with secondary antibody conjugated horseradish 
peroxidase followed by enhanced chemiluminescence (ECL) detection (ECL Plus, 
Amersham Pharmacia, Uppsala, Sweden) for paper IV, or (for paper II) incubated with 
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an IRDye ® 800CW conjugated secondary antibody (LI-COR, Nebraska, USA) 
followed by visualization of the proteins using the specialized imaging system.  
3.15 MICROARRAY DATA ANALYSIS SOFT WARE 
Data analysis was performed using Affymetrix GeneChip Operating Software (GCOS). 
A quantitative signal and a qualitative detection call were generated for each sample 
and transcript. Data files were subsequently analyzed utilizing the Gene Spring GX 
(Silicon Genetics, CA, USA) 
3.16 GENE EXPRESSION PATHWAY ANALYSIS SOFTWARE 
Enrichment analysis was performed using the online gene set analysis toolkit 
WebGestalt (http://bioinfo.vanderbilt.edu/webgestalt/) and Ingenuity pathway analysis 
for paper I. For other papers Panther tool were used.  
3.17 STATISTICAL ANALYSIS  
ANOVA test was used in paper II and III. Unpaired t-test was used for analysis of 
microarray results for paper IV. All the data are presented as mean ± SE.
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4 RESULTS  
4.1 PAPER I 
4.1.1 Establishment of acute GVHD   
Using different strains of donor and recipient mice, C57BL/6 as donors and BALB/c as 
recipient, induces lethal acute GVHD. The preliminary clinical signs of acute GVHD 
appear one week after allogeneic HSCT.  Clinical indications of GVHD (weight loss, 
hunched posture, poor activity, ruffled fur and loss of skin integrity) were observed in 
allogeneic-transplanted animals while the syngeneic group recovered to normal health 
conditions.  
Histological findings at day twenty one post transplantation in the skin and intestine of 
the allogeneic group confirmed the occurrence of GVHD while syngeneic-transplanted 
animals were identical to untreated mice (Figure 2).  
4.1.2 Gene expression after chemotherapy conditioning 
 Expressions of 164, 114 and 660 genes were changed in the liver, kidney and muscle, 
respectively, after chemotherapy conditioning (day 0).  
Genes involved in hemoglobin synthesis exclusively decreased in all tissues. 
Reciprocally, expression levels of only two genes, FK506-binding protein 5 and 
Vanin1, increased in all studied tissues after conditioning. 
Inflammation-related genes like CXCL1, IFN-induced GTPase (Igtp), signal 
transducers and activators of transcription  (STAT3) as well as intercellular adhesion 
molecule 1 (ICAM-1) were up regulated by 13, 2.8, 2.3 and 2.1 fold, respectively, in 
the liver, while not changing or decreasing in the kidney or muscle. 
JAK-STAT signaling pathway was significantly (P<0.0006) over expressed in the liver 
while no other tissues showed this pattern (Figure 3). Genes involved in this pathway, 
e.g. SOCS3, STAT3 and Cyclin D1, were significantly over expressed by 2.8, 2.3 and 
2.6 respectively in the liver after chemotherapy conditioning.   
Pathway analysis of over expressed genes in the kidney or muscle did not result in any 
biological processes.   
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Figure 2. Development of GVHD in allogeneic-transplanted mice versus syngeneic-
transplanted mice on day 21 after transplantation: (a) Skin of allogeneic-transplanted mice; (b) 
skin of syngeneic-transplanted mice; (c) intestine of allogeneic-transplanted mice; (d) intestine 
of syngeneic-transplanted mice  
4.1.3 Allogeneicity and inflammatory genes  
4.1.3.1 Liver 
621 and 590 genes totally were up and down regulated respectively in the liver of 
GVHD mice as compared to syngeneic-transplanted mice. A majority of over 
expressed genes in the liver of GVHD mice were related to immune response and 
inflammation. Genes which are important in antigen presentation, leukocyte migration 
and activation, were significantly up regulated in the liver of GVHD mice (P<0.001). 
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Figure 3.  JAK–STAT pathway in the liver. Arrows indicate over expressed genes. 
Toll-like receptor signaling (P<0.0026) and graft versus host disease (P<=9.28e-09) 
pathways were significantly provoked in the liver of GVHD mice, and this 
appropriately explains the pathophysiology of liver damage during GVHD. 
Interestingly, CD14 (22.7 FC), LBP (5.3 FC), TLR1 (5.3 FC) and TLR2 (7 FC) genes 
(targets for bacterial invasion and LPS stimulation) were significantly up regulated in 
liver tissue. None of these genes, biological processes or pathways increased in the liver 
of syngeneic-transplanted mice. These findings highlight the role of the innate immune 
system and importance of LPS extravasations in the pathogenesis of GVHD in the 
liver.   
4.1.3.2 Kidney 
The gene expression profile showed that numerous genes related to inflammation and 
immune response were up regulated in kidneys from mice developing GVHD while 
remaining unchanged or even decreasing in kidneys from syngeneic-transplanted mice.  
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The genes Chitinase 3-like 3 (955 fold), CXCL9 (72 fold), IFN-inducible GTPase 1 (72 
fold), IFNγ-inducible  protein 47 (49 fold), Histocompatibility 2, Q region (49 fold), 
Histocompatibility 2, class II, locus Mb2 (49 fold), Macrophage activation-2 like (45 
fold), Granzyme B (39 fold), Granzyme -K (34 fold), CD3 Ag, γ-polypeptide (34 fold) 
and CXCL11 (32 fold), which directly or indirectly are relevant to immune response 
and/or inflammation, were significantly up regulated in the kidneys of GVHD mice. 
Genes involved in antigen processing and presentation were highly expressed. 
4.1.3.3 Muscle 
In the muscle of GVHD mice, 3918 genes were either up or down regulated as 
compared to the syngeneic group. Among them, several inflammatory genes which 
mainly relate to systemic inflammation and cytokine effects were over expressed in the 
GVHD group. Although the majority of the pathways that involved up regulated genes 
(more than 70%) belonged to cell biological and metabolic clusters, less than 30% of 
them directed to antigen processing and presentation. Contrasting liver and kidney, the 
important genes for chemotaxis like IL-1-β, chemokines and adhesive molecules e.g. 
CXCL9, CXCL1, CCL1, Saa1, Saa3, STAT1 and VCAM either were not expressed or 
were significantly less expressed in the muscle. Thus, despite muscle of GVHD mice 
presenting more inflammatory genes than muscle from syngeneic-transplanted animals, 
they were still expressing much less inflammatory, chemotactic genes compared with 
the liver and kidneys of GVHD mice. 
4.1.4 Gene expression in target organs 
There was high up regulation in the expression of genes involved in immunological and 
inflammatory response in the liver and kidney compared to muscle in GVHD mice 
(Figure 4a). Moreover, the majority of the inflammatory related biological and 
molecular processes were up regulated in the liver or kidney but not in the muscle 
(Figure 4b).  
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Figure 4. Up regulated genes and biological process in target tissues versus non-target tissues 
in GVHD-developing mice. 
4.1.5 The kidney could be a target organ for acute GVHD 
311 genes were exclusively up regulated in the kidney of allogeneic-transplanted mice. 
These genes were unchanged or even decreased in kidneys from syngeneic-transplanted 
animals and also muscle from GVHD mice. Most of these genes were related to antigen 
presenting and immune response. The over expressed genes and activated  biological 
processes in the kidney are comparable to those observed in the liver (target tissue for 
GVHD) and are significantly different from those observed in muscle from GVHD 
mice (Figure 4). Furthermore, exploration of CD3+ T lymphocytes were confirmed in 
kidneys from allogeneic-transplanted mice but not in syngeneic-transplanted mice at 
day 21 after transplantation, which is similar to the results from the liver of mice 
transplanted with allogeneic bone marrow at the same time (Figure 5). 
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Figure 5. Infiltration of CD3+ T cells in the kidney of GVHD mice. (a) The liver, allogeneic 
(GVHD) group (b) the liver, syngeneic group (c) the kidney, allogeneic (GVHD) group (d) 
the kidney, syngeneic group. 
4.2 PAPER II 
4.2.1 PD-L1/CD274 in muscle, liver, and kidney 
In untreated animals, the expression of PD-L1/CD274 mRNA was significantly higher 
in muscle compared to liver (p<0.05). Furthermore, the expression of CD274 after 
conditioning (i.e. at D0) was increased by ten folds in muscle tissue compared to before 
conditioning D-7, whereas the increase was minimal in the liver and the kidney (Figure 
6).  
4.2.2 PD-L1 in target and non-target organs 
At the time of transplantation (D0) both syngeneic- and allogeneic-transplanted animals 
exhibited an increase in the expression of PD-L1 in all tested organs (Figure 7a-c). The 
syngeneic transplanted group showed a gradual decline in the expression of PD-L1 in 
all organs, starting on D+1 post transplantation.  In contrast, the allogeneic-transplanted 
group exhibited a continued significant (p<0.05) increase in the expression of this 
molecule, which peaked at day +5 (muscle and kidney) or +7 (liver) and then gradually 
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declined without reaching control levels even on day 21 post transplantation (Figure 7a-
c). 
4.2.3 Higher PD-L1 is in non-target organs  
On day +5, the fold-increase in the expression of PD-L1 in the muscle was significantly 
higher (p<0.01) than that in the kidney (28-fold) and liver (95-fold) (Figure 8a). The 
expression of PD-L1 was still significantly higher (p<0.05) in the muscle than in the 
kidney and liver 7 days after allogeneic transplantation, as measured by both qPCR and 
microarray (Figure 8b). 
 
Figure 6. PD-L1/CD274 mRNA expression in different organs in control (D-7) and 
conditioned (D0) mice. Samples from control mice (D-7) and conditioned mice (D0) were 
collected, mRNA was prepared and qPCR was performed. CD274 expression was calculated 
as a ratio to the house keeping gene (β actin; ACTB). The results are presented as mean ± SE. 
* significant difference (p< 0.05) 
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Figure 7. Dynamic expression of CD274 mRNA before and after bone marrow transplantation 
(syngeneic and allogeneic). Samples from control mice (D-7, before treatment), conditioned 
mice (D0) and allogeneic- and syngeneic-transplanted mice at different intervals (D+1, D+3, 
D+5, D+7 and D+21) from the muscle, kidney and liver were collected, mRNA was prepared 
and qPCR was performed. Normalized (PD-L1) expression was calculated relative to ACTB. 
The results are presented as mean ± SE. 
a. Muscle b. Kidney c. Liver 
*Statistically different (p<0.05) from the control value (D-7) as determined by the ANOVA 
test. 
¤ Statistically different (p<0.05) from the syngeneic-transplanted mice as determined by the 
ANOVA test. 
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Figure 8. Comparison of mRNA expression fold changes. Fold changes of mRNA expression 
post allogeneic transplantation relative to control. 
a. Fold changes (D+5) of mRNA for muscle and kidney and liver relative to controls (D-7).  
b. Fold changes (D+7) post allogeneic transplantation, compared to microarray data of 
mRNA fold changes at the same day  
** Significant (p<0.01) 
*** Significant (p<0.001) 
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4.2.4 PD-L1 at the protein level 
Western blot technique showed that mice receiving allogeneic transplants exhibited 
significantly increased levels of PD-L1 protein in all tested organs 5 days post 
transplantation. However, PD-L1 molecules in tissue samples from syngeneic-
transplanted mice at any time point did not express PD-L1 (Figure 9).These increased 
levels were more pronounced in the muscle and kidney and remained at the same level 
even on day 7 post transplantation (Figure 9). 
The immunohistochemical analysis also demonstrated that the expression of PD-L1 
was up regulated in the muscle, kidney and liver of transplanted mice 5 days post 
allogeneic transplantation, and that the strongest up-regulation was observed in 










Figure 9. PD-L1 expression at the protein level as determined by western blot. Samples were 
taken from control mice (D-7), conditioned mice (D0) and allogeneic- and syngeneic-
transplanted mice at different time points (D+5, D+7). Muscle, kidney and liver were collected, 
and the lysate was prepared and used for western blot. 
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Figure 10. Expression of PD-L1 by immunohistochemistry. Immunohistochemistry staining for 
PD-L1 was positive (arrow) after allogeneic transplantation compared to controls (D-7) in all 
tissues. The strongest PD-L1 staining was obtained in the endothelial cells. Magnification 40X 
was used in all slides. 
4.2.5 IFN-γ and TNF-α during acute GVHD development  
It has been shown that inflammatory cytokines, IFN-γ and TNF-α in particular, play a 
crucial role in the development of GVHD.[196] These cytokines are also shown to be 
involved in the induction of PD-L1 expression.[197] Therefore, we evaluated the 
production of IFN-γ and TNF-α in mice subjected to syngeneic or allogeneic 
transplantation. As shown in Figures 11a and 11b, serum levels of these cytokines were 
significantly (p<0.01) enhanced in all treated animals after Bu-Cy chemotherapy 
(day0). Moreover, the enhancement of IFN-γ and TNF-α serum levels was further 
potentiated in allogeneic- but not syngeneic-transplanted mice, exhibiting a peak on day 
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Figure 11. Kinetics of the production of inflammatory cytokines IFN-γ and TNF-α after 
chemotherapy based conditioning and transplantation with syngeneic or allogeneic bone 
marrow and splenic cells. Serum levels of (A) IFN-γ and (B) TNF-α, measured employing 
ELISA techniques. 
*Statistically different (p<0.05) from the control value (D-7) as determined by the ANOVA 
test. 
¤ Statistically different (p<0.05) from the syngeneic-transplanted mice as determined by the 
ANOVA test. 
4.3 PAPER III 
4.3.1  Gene expression after single-dose or fractionated TBI   
Conditioning with fractionated TBI resulted in up- and down-regulation of a total 1065, 
625 and 184 genes in the lung, muscle and liver respectively, while treatment with 
single-dose TBI specifically altered the expression of a total 3960, 30 and 17 genes in 
the same respective organs (Figure 12). 
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Figure 12. Effect of fractionated or single-dose total body irradiation (TBI) on the gene 
expression profile in the lung, liver and muscle. (a)Fractionated (b) Single-dose TBI after 
12h. 
Although, both conditioning regimens affected the lung predominantly, these regimens 
induce different patterns of gene expression in this organ, i.e. out of 3960 up and/or 
down regulated genes by single-dose TBI, only 74 genes are shared with those induced 
by the fractionated TBI (Figure 13).  
In the lung, fractionated TBI predominantly up regulated the genes related to 
inflammation and innate immunity (e.g. inflammatory cytokine production, Toll-like, 
interferon and interleukin receptor signaling). Furthermore, the magnitude of these up-
regulated genes in the lung did not exceed more than 4-fold.  In contrast, treatment with 
single-dose TBI largely down regulated the genes related to antigen presentation, 
inflammatory responses and innate immunity (e.g. inflammatory cytokine production, 
chemokines, interferon, and interleukin receptor signaling). However, this conditional 
regimen significantly up regulated the genes relating to the activation of natural killer 
(NK) cells. 
Together, these observations clearly imply that the lung is highly susceptible to both 
single-dose and fractionated TBI conditioning regimens. Moreover, single-dose TBI 
predominantly down regulated the genes related to immune and inflammatory response 
in the lung and this might, at least in part, explain why this conditioning regimen is 
more potent than fractionated TBI in induction of idiopathic interstitial 
pneumonia.[198] In addition, our observation that the genes of inflammatory responses 
were up regulated in the lung after administration of fractionated TBI implies that this 
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regimen might be more involved than the single-dose TBI in induction and 
development of pulmonary GVHD, a complication that requires inflammatory 
cytokines.[199] 
4.3.2 Kinetics of gene expression after single-dose TBI 
Evaluation of the kinetics of gene expression in the lung as well as the liver and muscle 
upon treatment with single-dose TBI showed that the total numbers of up- and down 
regulated genes were different in each organ (Figure14 a-c) at different time-points (6, 
12 and 72 hours). However, at each time-point, the lungs had the highest number of 
altered genes as compared to the liver and muscle (Figure 14a-c).  
 
 
Figure 13. Fractionated or single-dose total body irradiation (TBI) differentially affect the gene 
expression in the lung. 
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Figure 14. Kinetics of gene expression profiles in the lung, liver and muscle of mice 
conditioned with single-dose TBI after (a) 6h, (b) 12h and (c) 72h. 
Since the majority of immune-related genes were down regulated in the lung at 12h, we 
analyzed the alterations in these genes 6 and 72 hours after treatment with single-dose 
TBI. At 6h, this organ exhibited alterations in 109 immune-related genes of which only 
4 were up regulated. The down regulating effects were intensive and included the genes 
related to inflammation (e.g. chemokines, interferon, interleukin, toll-like and TNF 
receptor pathways), NK cell activation and antigen presentation pathway. 
Analysis of immune-related gene expression profile in the lungs 72 hours after 
treatment with single-dose TBI revealed that among 70 altered genes, 14 and 56 genes 
were up and down regulated, respectively. Again, the majority of down regulated genes 
were related to antigen presentation and inflammatory responses, in particular 
chemokines, interleukin, Toll-like and TNF receptor pathways and complement 
systems.  
On the other hand, few genes related to the chemokines, interleukin and toll-like 
receptor pathways and antigen presentation were among up regulated genes.  
In contrast to the lungs, single-dose or fractionated TBI induced alterations in few (3-
10) immune-related genes in the liver and muscle at any time point. In the liver, these 
alterations included both up- and down-regulations in the genes related to inflammatory 
responses, whereas in the muscle the altered genes belonged to inflammation as well as 
antigen presentation. 
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4.4 PAPER IV 
4.4.1 Gene expression profile in CKD derived monocytes 
A two way unsupervised hierarchical clustering showed that 600 genes were up 
regulated, and 272 down regulated, in CKD patients compared to healthy controls with 
P < 0.05 and fold changes of 1.5 and more (Figure 15). 
4.4.2 Pathway of up regulated genes in CKD patients  
Pathway analysis showed different pathways related to inflammation were up 
regulated. Wnt signaling pathway, inflammation mediated by chemokines and cytokine 
signaling, TGF-β signaling pathway, integrin signaling pathway and interleukin 
signaling pathway were the most highly up regulated in CKD patients (Table 1). 
 
Figure 15. Gene expression pattern in peripheral monocytes from three healthy subjects (H1, 
H2, H3) and three patients with CKD (P1, P2, P3) 
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Figure 16. Representative Western blot of CK1ε, DVL1, PGSKβ, GSKβ, β-catenin, and 
Tubulin from three healthy subjects and three CKD patients 
4.4.3 Wnt-β catenin pathway is activated in CKD monocytes 
 Different genes involved in the Wnt signaling pathway were up regulated in 
microarray gene expression results (Table 2).  Follow up experiments by Western blot 
confirmed the presence of proteins involved in this pathway (Figure 16). Normally, in 
the inactive state β-catenin exists within a protein complex consisting of Axin, APC 
(adenomatous polyposis coli), GSKβ (Glycogen synthase kinase), and CK1ε (Casein 
Kinase) which leads to phosphorylation and destruction of β-catenin and prevents its 
accumulation and passing to the nucleus.[200] Activation of the canonical pathway 
ensues when Wnt proteins interact with specific cell surface receptor complexes that 
consist of members of the Frizzled family and low-density lipid receptor (LRP)-5 or 
LRP6. This triggers phosphorylation of disheveled proteins (DVL) and promotes their 
interaction with the frizzled proteins.[201, 202] The DVL/receptor complexes facilitate 
phosphorylation of the LRP6 intracellular tails by the CK1ε. As a consequence, Axin is 
recruited to this receptor complex and the degradation of β-catenin by proteasome is 
blocked. This allows β-catenin to accumulate and enter the nucleus, where it interacts 
with members of the TCF/LEF family and converts them into potent transcriptional 
activators.[203-206] 
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Table 1. Pathways up regulated in monocytes collected from patients with CKD stages 4 and 5 
Name of pathway No. of genes 
Wnt signaling pathway 15 
Inflammation mediated by chemokine 
and cytokine signaling pathway 
12 
TGF β signaling pathway 7 
Integrin signaling pathway  6 
interleukin signaling pathway 5 
 
 






ANKRD6 1.6 Ankyrin repeat domain-containing protein 6 
CDH15 1.7 Cadherin-15 
CDH19 4.5 Cadherin-19 
CDH8 3.2 Cadherin-8 
DKK2 5 Dickkopf-related protein 2 
EDN1 2.1 Big endothelin-1 
FZD4 1.8 Frizzled-4 
MYH8 1.9 Myosin-8 
NFATC4 1.9 Nuclear factor of activated T-cells, cytoplasmic 4 
PCDHA5 5.9 Protocadherin alpha-5 
PCDHA9 2 Protocadherin alpha-9 
PPARD 3.8 Peroxisome proliferator-activated receptor delta 
PPP2R5C 1.9 
Serine/threonine-protein phosphatase 2 regulatory subunit 
gamma isoform 
TCF3 2.2 Transcription factor 7-like 1 
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Figure 17. Densitometry of western blot from fourteen patients and ten healthy subjects. 
Tubulin was used to normalize the results of β-catenin, DVL1 and CK1ε while GSKβ was used 
to normalize PGSKβ. 
 A) PGSK (p< 0.01), B) CK1ε (p<0.0001), C) DVL1 (p<0.00001) and D) β-catenin (p<0.05)  
Both of the Figures (16) and (17a-d) show the Western blot and densitometry for 
quantification of β-catenin, GSKβ, PGSKβ, DVL1 and CK1ε respectively.  The protein 
concentration is significantly different between the patients and the healthy group. β-
catenin, which is the main protein in this pathway, was significantly more expressed in 
the patient group (P< 0.05). There was no difference in total GSKβ between the healthy 
and the patient groups, but the phosphorylated GSKβ (P GSKβ) was significantly more 
expressed in healthy subjects than in patients (P<0.01). DVL1 and CK1ε were 
significantly more expressed in patients compared to in healthy subjects (P<0.00001 
and P<0.0001, respectively). 
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5 DISCUSSION 
Using microarray technique for global gene expression analysis provides a picture of all 
the transcriptional activity in a biological sample [207, 208] and thus facilitates the 
discovery of the changes in expression in a huge number of genes at the same time. It 
has been used widely to discover the marker of diseases and to understand more about 
the pathogenesis of the disease. In this thesis, the involvement of the immune system in 
pathogenesis of different diseases has been discussed thoroughly. Microarray gene 
expression was initially used as the main method to discover what is taking place.  
HSCT has been used widely as the treatment of choice for several different malignant 
and nonmalignant conditions. Despite that, this type of treatment is accompanied by 
multiple side effects that hinder its use. Preparation for this treatment (i.e. conditioning) 
involves high risk in itself. Moreover, development of major complications, mainly 
GVHD, is a big obstacle in the way of successful HSCT. Different reports have shown 
that tissue damage due to conditioning and the following cytokine storm to be an 
important factor in initiating and developing GVHD [81, 163, 170, 209] 
  In our first study, gene expression profiles in different organs in the early stages of 
acute GVHD were studied. Organs differ in their liability to be affected by GVHD; 
some organs like liver and skin are more vulnerable.[210] Therefore, we wanted to 
expose the molecular changes in different organs after conditioning and HSCT and the 
development of acute GVHD. The finding that expression of CXCL1, ICAM1 and 
STAT3 along with the JAK–STAT pathway was significantly higher in the liver after 
chemotherapy conditioning suggested local inflammation and/or toxicity.  The over 
expression of STAT3 in the liver, which is a mediator of the acute phase of the 
inflammatory response, could be caused by local tissue damage and inflammation 
observed in liver histology after conditioning.  
An interesting finding was that during GVHD, progressive over expression of 
inflammatory genes was found in different organs in almost all tissues in allogeneic 
setting. This observation indicates the importance of allogeneicity and the role of donor 
cells in gene expression profile reflecting systemic inflammation at day +7.[211, 212]  
However, the differences in expression levels of these genes and/or relevant pathways 
in the liver and kidney of GVHD mice were significantly higher than those in the 
muscle of GVHD mice. Although 90% of biological processes and pathways in the 
liver and kidney of GVHD mice were related to inflammatory processes, only 25 to 
30% of up regulated processes in the muscle belonged to these clusters. 
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Histopathological staining of the kidney of GVHD mice confirmed the presence of T 
cells (similar to that observed in the liver) indicating T-cell invasion to this organ after 
developing GVHD. Together these data indicate that the gene expression profile of the 
kidney in allo-SCT is comparable to that of the liver. However, expression patterns of 
inflammatory processes and immune response pathways in the kidney are different 
from those in the liver. It seems that these two organs experience different pathways 
provoking inflammation and immune response after allo-SCT and initiation of the 
GVHD process.  
The impact of T cells on GVHD is well known, but the development of inhibiting 
factors or suppressing factors to the work of these T cells during the process of GVHD 
development is also important to consider. Therefore, we proceeded further in the 
second study to find out the kinetic of expression of PD-L1 in different organs known 
to be affected by GVHD and those known to be less affected by GVHD. In the past few 
years, different studies have focused on exploring the role of CD274 during 
HSCT.[213-215] However, results from microarrays in the first study revealed PD-
L1/CD274 as the most highly expressed gene in the muscle on the seventh day after 
allogeneic transplantation. 
PD-L1 is known for its inhibitory effect on activated T cells during its interaction with 
the PD-1 receptor on the surface of these cells.[216, 217]  Expression of PD-L1 mRNA 
in the skeletal muscle of untreated control mice (D-7) was higher than that in the liver 
and kidney, and this strongly suggests that skeletal muscle constitutively expresses 
more PD-L1. The increase in mRNA levels of PD-L1 in all tested organs upon 
conditioning with Bu-Cy implies the possibility that conditioning-induced cytokine 
storm is responsible for the up-regulation of PD-L1 in different organs. In fact, this 
possibility is supported by our finding that serum levels of IFN-γ and TNF-α are 
significantly increased by conditioning prior to syngeneic or allogeneic transplantation.  
The finding that PD-L1/CD274 was more expressed in the muscle, which is usually 
regarded as non- target organ, in acute GVHD supports the idea that PD-L1 may play 
an important role in protection of organs against developing GVHD. Moreover, its 
expression was more in the kidney than in the liver and this further strengthens the idea 
that it may protect organs during GVHD, or at least delay it. However, a question of 
chronicity arises, since it has been found that prolonged PD-L1 expression causes 
exhaustion of T cells and leads to the development of chronic inflammation.[218, 219]  
Conditioning has been known to be associated with cytokine storm. However, 
conditioning is not a specific therapy; nearly all organs are affected by its toxic effects. 
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Optimization of the conditioning regimen is a critical point in reducing treatment 
related toxicity. Several reports addressed the effect of TBI given as single dose or in 
fractionated form, alone or in combination with cyclophosphamide. However, thorough 
investigations of the immunological effects of different strategies for providing TBI 
conditioning to different organs were missing.  Therefore, in the third study the 
immunological effects of different strategies to provide TBI, single dose or 
fractionated, to different organs were investigated. The observation that single-dose 
(but not fractionated) TBI suppresses the expression of several genes related to both the 
innate and adaptive immune system suggests the tendency to develop interstitial 
pneumonitis after this type of conditioning. In particular, this applies to the major 
histocompatibility complex type II-associated invariant chain CD274, which is highly 
expressed by type II alveolar epithelial cells,[220].  Since histocompatibility 
importance in the pathogenesis of GVHD is well known, the observation that 
histocompatibility genes were strongly down regulated after single dose TBI further 
strengthens the idea that the incidence of pulmonary GVHD is lesser after single dose 
TBI. There is also higher risk of developing interstitial pneumonitis than pulmonary 
GVHD.  In addition, our observation that the genes of inflammatory responses were up 
regulated in the lung after administration with fractionated TBI implies that this 
regimen might be more involved than the single-dose TBI in induction and 
development of pulmonary GVHD, a complication that requires inflammatory 
cytokines.[199] 
However, the low magnitude of the changes in the gene expression after fractionated 
TBI infers that in general the splitting of dose induces less effect on tissues even when 
the total dose is similar to that administered in single dose TBI. 
It is clear that the changes in the expression of genes leading further to production of 
different proteins on immune related cells is an issue worth studying during a course of 
immunological related disorder. Therefore, during our fourth project we attempted to 
find the gene expression changes in monocytes, which are critical cells in the immune 
system. We then studied these changes in monocytes from peripheral blood from 
chronic kidney disease patients, who are known for their low immunity and hence high 
liability to get infections.[177] Moreover, this patient group is characterized by a high 
mortality rate from cardiovascular complications, especially atherosclerosis.[221-223] 
Since monocytes are critical in the pathogenesis of atherosclerosis, [16, 224] the study 
of changes in gene expression in monocytes from CKD patients is important. 
Surprisingly, the gene expression showed a distinct difference between patients and the 
healthy group. Genes involved in pathways related to immune response and cell 
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adhesion were up regulated. Furthermore, an important signaling pathway, the Wnt/β-
catenin pathway, was significantly different in both groups. Activation of this pathway 
leads to accumulation of β-catenin in the cytoplasm, which has two impacts. First it will 
pass to the nucleus and help in activation of transcription factor; secondly this β-catenin 
by itself increases the adherence abilities of the monocytes to the endothelium.[225, 
226]  Moreover, Wnt5a has been associated with increased IL6 production in the 
macrophages.[227] Since this group of patients suffers from low grade inflammation 
[188] we concluded that this pathway is critical in the dysfunction of monocytes in 
CKD, and that interference with this pathway may improve quality of life in these 
patients regarding immunity and CVS complications. 
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6 CONCLUSIONS  
The studies involved in this thesis have shown: 
 The inflammatory response that occurs during early acute GVHD is a general 
response that occurs even in organs that are not targets for acute GVHD, but to 
a lesser extent.  
 Other organs than the usual known target organs for acute GVHD such as the 
kidney could be silent target organs for acute GVHD or may be late affected 
organs. 
 PD-L1 could have a protective role against acute GVHD, may delay its 
development or may make it latent. 
 Single dose and fractionated TBI produce different immunological responses in 
different organs. 
 Wnt/β-catenin signaling is activated in monocytes from CKD patients. 
Interference with this pathway may improve immune function and reduce 
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